ALX Oncology's Q1 2026 Earnings: CD47 Biomarker Emerges as Key Predictor in HER2-Positive Breast Cancer

In its first quarter 2026 earnings call, ALX Oncology Holdings Inc. (NASDAQ: ALXO) unveiled promising clinical insights that could reshape targeted therapies for HER2-positive breast cancer. Presented at the ESMO Breast 2026 conference in Munich, the data highlighted that all confirmed HER2-positive patients with high CD47 expression achieved a clinical response, including one complete response, when treated with evorpacept in combination with zanidatamab. This outcome underscores the potential of CD47 as a predictive biomarker, validating ALX's CD47-selection hypothesis and offering a data-driven path to improve response rates in oncology.

The company's market opportunity assessment estimates approximately 20,000 HER2-positive and CD47-overexpressing patients in the U.S. and five major European markets. This patient population represents a significant addressable market, particularly as HER2-positive breast cancer remains a leading cause of cancer-related mortality despite advances like trastuzumab and pertuzumab. By focusing on CD47-high expressors, ALX Oncology aims to enhance durable clinical responses, potentially differentiating evorpacept from broader CD47 inhibitors that have faced toxicity challenges in the past.

Clinical Trial Highlights and Data Breakdown

The ESMO presentation drew from two independent HER2-positive trials, where evorpacept—a next-generation CD47 blocking therapeutic—demonstrated consistent efficacy. In patients receiving evorpacept plus zanidatamab, a bispecific antibody targeting HER2, the results showed durable responses exclusively in those with elevated CD47 expression. The median duration of response was not yet reached in the dataset, suggesting prolonged benefit potential.

CD47, often dubbed the 'don't eat me' signal, inhibits macrophage-mediated phagocytosis of cancer cells. ALX's approach leverages this pathway selectively, combining it with HER2-targeted agents to overcome resistance mechanisms. GuruFocus reported that the analysis confirmed 100% clinical response rate in the CD47-high cohort, with one patient achieving complete response. This binary outcome—response in all qualifying patients—strengthens confidence in patient selection strategies, a critical factor for regulatory success and commercial viability.

Financially, ALX Oncology reported its Q1 2026 results alongside this update, maintaining a lean cash position sufficient into mid-2027, per standard biotech burn rates. While specific revenue figures were not detailed in the releases, the focus remained on pipeline derisking rather than topline growth, typical for a clinical-stage biotech.

Implications for Biotech Pipelines and Competitive Landscape

This data arrives at a pivotal moment for immuno-oncology. CD47 blockers have historically struggled with anemia and other on-target toxicities when used monotherapeutically. ALX's evorpacept, engineered with a differentiated Fc domain, appears to mitigate these issues in combinations, as evidenced by the clean safety profile in HER2 trials. The CD47-selection hypothesis now has empirical support, potentially accelerating enrollment and trial efficiency by pre-screening responsive patients.

In the broader biotech sector, this bolsters confidence in biomarker-driven development. Companies like Zymeworks (zanidatamab's developer) and others in HER2 space—such as MacroGenics or Seagen (now Pfizer)—stand to benefit indirectly through combo opportunities. ALX's 20,000-patient estimate aligns with epidemiology data from sources like the American Cancer Society, where HER2-positive cases comprise 15-20% of breast cancers, and CD47 overexpression correlates with aggressive subtypes.

Regulatory-wise, the FDA has shown receptivity to biomarker-enriched trials, as seen in recent approvals like Enhertu for HER2-low cancers. ALX's data could support accelerated pathways, particularly if pivotal trials confirm these early signals. The ESMO 2026 Congress timing—within the last 24 hours as of May 9-10—amplifies visibility, likely contributing to today's trending status in biotech news feeds.

Market Reaction and Stock Implications

ALXO shares have trended positively on this news, reflecting investor appetite for derisked assets in a volatile biotech market. GuruFocus and Intellectia.AI coverage emphasized the 'promising data,' with implications for path derisking in HER2-positive indications. While exact trading volumes from May 9 are not quoted here, the confluence of earnings and clinical readout typically catalyzes 20-50% moves in micro-cap biotechs like ALX (market cap under $100M pre-news).

Comparatively, the XBI biotech index has gained modestly year-to-date 2026, buoyed by M&A activity and trial successes. ALX's update fits this narrative, positioning it as a speculative buy for those bullish on precision oncology. Risks remain—small sample sizes (likely n<20 per cohort) necessitate larger datasets—but the 100% response rate sets a high bar.

Broader Impact on Pharma and Regulatory Environment

For big pharma, this signals combo potential. Jazz Pharmaceuticals, ALX's partner in earlier studies, could expand collaboration, while Roche/Genentech's HER2 dominance faces nuanced competition in CD47+ niches. The data reinforces a shift toward rational combinations, reducing failure rates that plague 90% of oncology trials.

Clinically, it derisks evorpacept's path in breast cancer, with potential readouts in gastric and other HER2+ solid tumors. ALX estimates U.S./EU5 prevalence at 20,000, but global expansion could double this, per WHO cancer stats. Peak sales models, conservatively, project $500M+ for niche HER2+ agents, akin to tucatinib's trajectory.

Regulatory tailwinds include FDA's Project Optimus for dose optimization and biomarker qualification programs. ESMO's platform further validates CD47 as a companion diagnostic target, paving for co-developed tests.

Investment Thesis and Forward Outlook

Bullish investors view ALX as undervalued, with catalysts including Q2 data updates and partnership expansions. The CD47-selection strategy mirrors successes like Keytruda's PD-L1 enrichment, de-risking Phase 3. Neutral observers await PFS/OS data, but early signals are unequivocally positive.

In summary, ALX Oncology's Q1 2026 disclosures, anchored by ESMO Breast data, mark a milestone for CD47 therapeutics. By honing on high-expressors, ALX enhances response predictability, impacting pipelines, stocks, and the regulatory paradigm. As biotech rebounds, this positions ALX favorably amid sector optimism. Monitor upcoming trials for confirmation, but the trajectory points upward.

Word count: 1,056. Data sourced from Intellectia.AI, GuruFocus, and ALX releases dated May 9, 2026.